GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity

Mark D. Bunting, Antiopi Varelias, Fernando Souza-Fonseca-Guimaraes, Iona S. Schuster, Katie E. Lineburg, Rachel D. Kuns, Peter Fleming, Kelly R. Locke, Nicholas D. Huntington, Bruce R. Blazar, Steven W. Lane, Siok Keen Tey, Kelli P A MacDonald, Mark J. Smyth, Mariapia A. Degli-Esposti, Geoffrey R. Hill

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Allogeneic bone marrow transplantation (allo-BMT) is a curative therapy for hematological malignancies, but is associated with significant complications, principally graft-versus-host disease (GVHD) and opportunistic infections. Natural killer (NK) cells mediate important innate immunity that provides a temporal bridge until the reconstruction of adaptive immunity. Here, we show that the development of GVHD after allo-BMT prevented NK-cell reconstitution, particularly within the maturing M1 and M2 NK-cell subsets in association with exaggerated activation, apoptosis, and autophagy. Donor T cells were critical in this process by limiting the availability of interleukin 15 (IL-15), and administration of IL-15/IL-15Rα or immune suppression with rapamycin could restore NK-cell reconstitution. Importantly, the NK-cell defect induced by GVHD resulted in the failure of NK-cell-dependent in vivo cytotoxicity and graft-versus-leukemia effects. Control of cytomegalovirus infection after allo-BMT was also impaired during GVHD. Thus, during GVHD, donor T cells compete with NK cells for IL-15 thereby inducing profound defects in NK-cell reconstitution that compromise both leukemia and pathogen-specific immunity.

Original languageEnglish (US)
Pages (from-to)630-642
Number of pages13
Issue number5
StatePublished - Feb 2 2017

Bibliographical note

Funding Information:
The authors acknowledge Michelle Teng for her critical reading of the manuscript. This work was supported by research grants from the National Health and Medical Research Council (NHandMRC). F.S.-F.-G. was supported by a NHandMRC Early Career Research Fellowship and National Breast Cancer Foundation Fellowship. S.W.L. was supported by a NHandMRC Career Development Fellowship. M.A.D.-E. was a NHandMRC Principal Research Fellow. M.J.S. and G.R.H. were NHandMRC Senior Principal Research Fellows. G.R.H. was a QLD Health Senior Clinical Research Fellow. B.R.B. was supported by National Institutes of Health National Cancer Institute grant R01 CA72669.

Fingerprint Dive into the research topics of 'GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity'. Together they form a unique fingerprint.

Cite this